** Shares of drug developer Veradermics MANE.N rise 6.3% to $117.14 premarket

** Co says its experimental oral hair loss drug, VDPHL01, met the main goal in a mid-stage study in women with female pattern hair loss, a common condition that causes gradual hair thinning

** Says 89% of women on once-daily treatment and 90% on twice-daily treatment reported improved hair coverage after six months

** Patients grew about 23 additional hairs per square centimeter on average in the treated area, co says

** Co expects data from an ongoing mid- to late-stage trial in women in H1 2027 and from a late-stage study in men in H2 2026

** Shares have risen ~12% since the co's February 4 IPO, based on last close